Search

Pulmonary delivery of drugs has attracted increasing attention in healthcare, as the lungs are an easily accessible site for noninvasive systemic delivery of drugs. Although pulmonary inhalation of porous microparticles has been shown to sustain drug delivery, there are limited reports on efficient delivery of insulin and inhalation therapy of diabetes based on supercritical carbon dioxide (SC‐CO2) technology. Herein, this study reports the fabrication of insulin‐loaded poly‐l‐lactide porous microspheres (INS‐PLLA PMs) by using the SC‐CO2technology, and their use as an inhalation delivery system potentially for diabetes therapy. Biocompatibility and delivery efficiency of the PLLA PMs in the lungs are investigated. The PLLA PMs show negligible toxicity to lung‐derived cells, resulting in no significant reduction in cell viability, as well as levels of various inflammatory mediators such as interleukin (IL)‐6, IL‐8, and tumor necrosis factor‐α, compared with the negative control group. INS‐PLLA PMs are further efficiently deposited in the trachea and the bronchi of superior lobes of the lungs, which exhibit pronounced hypoglycemic activity in induced diabetic rats. Together, the results demonstrate that the INS‐PLLA PMs have a strong potential as an effective strategy for inhalation treatment of diabetes. Highly efficient insulin‐loaded poly‐l‐lactide porous microspheres (INS‐PLLA PMs)are fabricated using the supercritical carbon dioxide technology for their use as an inhalation delivery system potentially for diabetes therapy. These biocompatible INS‐PLLA PMs can be efficiently deposited in the trachea and the bronchi of superior lobes of the lungs, which exhibit pronounced hypoglycemic activity in the induced diabetic rats.